| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Paulson & Co John Paulson | 73.26M | $509.13M | NEW |
| Citadel Ken Griffin | 2.20M | $15.31M | NEW |
| D.E. Shaw David Shaw | 1.68M | $11.68M | NEW |
| Renaissance Technologies Jim Simons (founder) | 1.43M | $9.95M | NEW |
| Point72 Steve Cohen | 1.36M | $9.45M | NEW |
| Marshall Wace | 604K | $4.20M | NEW |
Bausch Health Companies Inc. is a diversified healthcare company focused on developing, manufacturing, and marketing branded and generic pharmaceuticals, over-the-counter products, and medical devices. Its portfolio spans gastroenterology, neurology, dermatology, and eye health, with a notable legacy from the acquisition of Bausch + Lomb that established a strong footprint in vision care and ophthalmic pharmaceuticals. Operating within the specialty and generic drug segment, the company emphasizes treatments for chronic conditions and niche therapeutic areas where physician-led adoption and patient adherence are critical. Bausch Health serves patients, healthcare professionals, and institutional buyers across global markets through a mix of prescription brands, generics, and consumer health offerings. The firm’s scale—supported by a large employee base—enables integrated R&D, manufacturing, and distribution, positioning it as a meaningful player in cost-sensitive and specialty therapeutics. Financially, it exhibits characteristics of a value-oriented healthcare issuer, reflecting low price-to-sales and active capital allocation underpinned by ongoing operating profitability metrics.
Earnings calendar coming soon. Subscribe to get notified when BHC reports next.
Get earnings alerts →